Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Form 144 filed reporting a proposed sale of 14,640 shares of Common Stock. The filing lists the sale as an Exercise of Stock Options with proceeds shown and a trade date of 04/01/2026. The submission also lists multiple prior 10b5-1 sales by Jeremy Chadwick in March 2026, including 91,250 shares on 03/23/2026 and 24,727 shares on 03/25/2026.
KYMR affiliate reported multiple sales of Common Stock under a Rule 10b5-1 plan and an exercise-based sale. The filing lists 10b5-1 dispositions on 03/25/2026 (24,727 shares, $1,984,554.44), 03/23/2026 (91,250 shares, $7,063,733.26), 03/11/2026 (25,758 shares, $2,145,673.70), and earlier March trades. The filing also shows an exercise of stock options for 7,600 shares on 03/31/2026 with cash consideration.
Kymera Therapeutics, Inc. reported that its Board of Directors approved an immediate amendment to the company’s Second Amended and Restated Bylaws. The change designates the federal district courts of the United States as the exclusive forum for any complaints asserting causes of action under the Securities Act of 1933 or the Securities Exchange Act of 1934, and related regulations, unless the company agrees in writing to a different forum.
The amendment aligns the company’s bylaws with recent changes to the Delaware General Corporation Law regarding forum selection provisions. The full text of the amendment is provided as an exhibit to the report for shareholders and other stakeholders who want to review the precise language.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares of Kymera Therapeutics Inc. common stock. The filing states that an internal realignment effective January 12, 2026 led certain Vanguard subsidiaries/divisions to report holdings separately under SEC Release No. 34-39538. The amendment, signed 03/27/2026, lists 0 shares beneficially owned and 0% ownership of the class.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and share sales in Kymera Therapeutics, Inc. common stock. He exercised stock options to acquire 109,127 shares at an exercise price of $29.64 per share and then sold 115,977 shares of common stock in multiple open-market transactions at weighted average prices ranging from the mid-$70s to about $80 per share, as detailed in the footnotes. Following these transactions, he directly held 61,202 shares of Kymera common stock. The filing states that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily.
KYMR notice reports Rule 144 transactions in Common stock by an insider and planned issuer-related issuances. The filing lists 109,127 shares tied to an exercise of stock options on 03/23/2026 and 6,850 shares issued as Restricted Stock Units on 03/01/2026. The filing also discloses recent 10b5-1 sales: 25,758 shares on 03/11/2026 for $2,145,673.70, 3,919 shares on 03/04/2026 for $334,272.49, and 2,039 shares on 03/02/2026 for $181,321.64.
Kymera Therapeutics director Pamela Esposito exercised options for 2,500 shares of Common Stock at an exercise price of $49.10 per share and sold all 2,500 shares the same day. The sales were executed in three open-market transactions at weighted average prices of $77.71, $79.24 and $79.94 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated September 17, 2025, meaning the trades were scheduled in advance rather than timed discretionarily.
KYMR submitted a Form 144 notice disclosing the proposed sale and recent dispositions tied to an option exercise and 10b5-1 programs. The filing shows an exercise of stock options for 2,500 shares on 03/20/2026 for cash. It also lists prior 10b5-1 sales by Pamela Esposito: 2,500 shares on 02/20/2026 and 5,500 shares on 01/20/2026, with proceeds shown for each transaction.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick exercised stock options for 20,000 shares of common stock at an exercise price of $43.50 per share. He then sold a total of 25,758 shares of common stock in open-market transactions at weighted average prices of $82.1275, $83.1013, and $83.7195 per share, as part of multiple trades within specified price ranges.
The filing states these transactions were completed under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025. Following the transactions, Chadwick directly holds 68,052 shares of Kymera Therapeutics common stock.